10-Q quarterly report · filed Nov 2, 2026

CRISPR Therapeutics AG (CRSP) Q3 2026 10-Q Quarterly Report

Short answer

CRISPR Therapeutics AG (CRSP) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M (up 1325.1% year over year) with net income of −$111M.

Q3 2026 key financials · XBRL

Revenue
$13M
+1325.1% YoY · +24.4% QoQ
Net income
−$111M
−4.7% YoY · −22.3% QoQ
Operating margin
-1026.5%
EPS (diluted)
−$1.16
−1.8% YoY · −23.4% QoQ

Source: XBRL data from the CRISPR Therapeutics AG (CRSP) Q3 2026 10-Q on SEC EDGAR. USD.

CRISPR Therapeutics AG Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $12.7M vs $0.0M YoY, primarily $12.3M deferred Vertex collaboration revenue
  • Net loss $111.4M vs $106.4M YoY, operating loss $130.0M vs $132.1M
  • R&D expense $71.9M vs $58.9M, worst cost increase external R&D $25.1M vs $14.9M
  • Cash, equivalents and securities $2,276.6M; operating cash used $282.1M for nine months
  • $585.4M net convertible-note proceeds; cash runway at least 24 months, additional financing expected for long-term development

Risk Factors

  • No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
  • Continued business, financial condition, and operating-results exposure from previously disclosed risks
  • Prior-quarter risk disclosures remain applicable through the quarter ended March 31, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CRISPR Therapeutics AG quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.